Hospital for Special Surgery

University Health Network

Carl Peter Blobel

Tak Wah Mak

Marjana Tomic

Thorsten Maretzky

David McIlwain

Asheesh Harsha

Disclosed are methods for treating a subject with an EGFR dependent pathology. The method comprises the step of administering to the subject an effective amount of an agent ('First Agent') that decreases the biological activity of iRhom1 and an effective amount of an agent ('Second Agent') that decreases the biological activity of iRhom2. Alternatively, the method comprises the step of administering to the subject an effective amount of an agent (&#x201c;First Agent&#x201d;) that modulates formation of a complex between iRhom 1 and TACE and an effective amount of an agent (&#x201c;Second Agent&#x201d;) that modulates formation of a complex between TACE and iRhom2. Also disclosed are assays for identifying such agents.

Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2

Provided herein are compositions and methods that inhibit expression of Adam12 gene products, such as ADAM12 mRNA and/or ADAM12 polypeptides, as a therapeutic approach for the treatment of, or promotion of healing of, wounds.

Methods and compositions for promoting wound healing

Growing community of inventors

Eastchester, NY, United States of America

Carl Peter Blobel